Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

Abstract

Background: The role of serum fibroblast growth factor 19 (FGF19) in arteriosclerosis is not well known. In the present study, we aimed to explore whether serum FGF19 levels were related to arteriosclerosis parameters, including arterial stiffness and atherogenic index of plasma (AIP), in patients with type 2 diabetes (T2D). Methods: A total of 200 patients with type 2 diabetes and 50 healthy controls were recruited for this study from Apr 2017 to Oct 2018. Serum FGF19 levels, arterial stiffness assessed by brachial ankle pulse wave velocity (baPWV), and AIP assessed by the triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) ratio were measured in those subjects. In addition, other relevant clinical data were also collected. Results: Serum FGF19 levels in T2D patients were significantly lower than those in healthy controls (p < 0.05). The arteriosclerosis parameters, including baPWV and AIP, significantly decreased across ascending tertiles of serum FGF19 levels (all p for trend < 0.001). Moreover, the baPWV and AIP were all inversely correlated with serum FGF19 levels (r = − 0.351 and − 0.303, respectively, p < 0.001). Furthermore, after adjusting for other clinical covariates by multiple linear regression analyses, the serum FGF19 levels were independently associated with baPWV (β = − 0.20, t = − 2.23, p = 0.029) and AIP (β = − 0.28, t = − 2.66, p = 0.010). Conclusions: The serum FGF19 levels were independently and inversely associated with baPWV and AIP, which indicate that serum FGF19 may have a protective role in atherosclerosis in patients with T2D.

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

“…The following four causes led to the exclusion of a 14 further articles: two publications were conference abstracts [ 37 , 38 ]; two of the publications were posters [ 39 , 40 ]; one study involved patients with polycystic ovarian syndrome [ 41 ]; one study enrolled patients under the age of 18 [ 42 ]; one study involved no imagistic or histopathological confirmation of hepatic steatosis [ 43 ]; and seven publications were interventional studies [ 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. Eight publications in total [ 4 , 5 , 51 , 52 , 53 , 54 , 55 , 56 ] were included in the systematic review, and six of these [ 4 , 5 , 51 , 52 , 55 , 56 ] were also included in the meta-analysis.…”

New developments in the biology of fibroblast growth factors

“…In contrast, in HFD-fed ApoE À/À mice, phosphorylation of hepatic farnesoid X receptor by FGF15/19 signaling maintained serum cholesterol levels and protected against atherosclerosis (Byun et al, 2019). In patients with type 2 diabetes (T2D), serum FGF15/19 levels are independently and inversely associated with arteriosclerosis parameters, supporting a protective role for serum FGF15/19 in atherosclerosis progression (W. S. Liu, Tang, et al, 2020). FGF21 also mitigates atherosclerosis in HFD-fed ApoE À/À mice (Maeng et al, 2020).…”

Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms

“…Epidemiological Evaluations: Because laboratory evidence suggests that higher concentrations of PFAS may down-regulate CYP7A1 activity ( Beggs et al, 2016 ; Behr et al, 2020a ; Schlezinger et al, 2020 ), it would be of interest to conduct an epidemiologic study to examine serum biomarkers of CYP7A1 (7α-hydroxy-4-cholesten-3-one (C4), specific bile acids, and fibroblast growth factor 19) in relation to PFAS exposure ( Gälman et al, 2003 ; Liu et al, 2020 ; Palmer et al, 2018 ), especially in occupationally-exposed groups where some subjects have high serum levels, e.g., 10 μg/mL or more PFOA or PFOS.…”